Literature DB >> 2863225

Amplification of the c-myc oncogene in human plasma-cell leukemia.

J Sümegi, T Hedberg, M Björkholm, T Godal, H Mellstedt, M G Nilsson, C Perlman, G Klein.   

Abstract

We have examined primary leukemia cells from multiple myeloma and plasma-cell leukemia patients for rearrangement, amplification and expression of c-myc oncogene. No rearrangement or detectable amplification of the c-myc could be found in 21 cases of multiple myeloma. In contrast, 2/3 cases of plasma-cell leukemia showed amplification of the oncogene with concomitant higher level of expression.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2863225

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 2.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

3.  A single nucleotide change in the c-myc internal ribosome entry segment leads to enhanced binding of a group of protein factors.

Authors:  F E Paulin; S A Chappell; A E Willis
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

4.  Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.

Authors:  D D Biggs; P Kraj; J Goldman; L Jefferies; C Carchidi; K Anderson; L E Silberstein
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 5.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

6.  Complex translocation disrupts c-myc regulation in a human plasma cell myeloma.

Authors:  G F Hollis; A F Gazdar; V Bertness; I R Kirsch
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

7.  Structure and expression of B-myc, a new member of the myc gene family.

Authors:  S Ingvarsson; C Asker; H Axelson; G Klein; J Sümegi
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

8.  Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma.

Authors:  G Kovacs; R Erlandsson; F Boldog; S Ingvarsson; R Müller-Brechlin; G Klein; J Sümegi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.

Authors:  H Rosenbaum; A W Harris; M L Bath; J McNeall; E Webb; J M Adams; S Cory
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.